Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
Clinical trial NCT02974153 · COMPLETED
Trial details
- NCT number
- NCT02974153
- Sponsor
- Alder Biopharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-01
- Primary completion
- 2017-11-01
- Enrollment
- 1121
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.